Ardeshir Bayat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4366801/publications.pdf

Version: 2024-02-01

244 papers	11,323 citations	25423 59 h-index	48101 92 g-index
245 all docs	245 docs citations	245 times ranked	11024 citing authors

#	Article	IF	Citations
1	In Vitro,Ex Vivo, andIn VivoApproaches for Investigation of Skin Scarring: Human and Animal Models. Advances in Wound Care, 2023, 12, 97-116.	2.6	6
2	Noninvasive Objective Tools for Quantitative Assessment of Skin Scarring. Advances in Wound Care, 2022, 11, 132-149.	2.6	0
3	Genetics and Epigenetics of Keloids. Advances in Wound Care, 2022, 11, 192-201.	2.6	13
4	Energyâ€based devices for the treatment of Acne Scars: 2022 International consensus recommendations. Lasers in Surgery and Medicine, 2022, 54, 10-26.	1.1	33
5	Controlling Inflammation Pre-Emptively or at the Time of Cutaneous Injury Optimises Outcome of Skin Scarring. Frontiers in Immunology, 2022, 13, .	2.2	1
6	Assessment of Transdermal Delivery of Topical Compounds in Skin Scarring Using a Novel Combined Approach of Raman Spectroscopy and High-Performance Liquid Chromatography. Advances in Wound Care, 2021, 10, 1-12.	2.6	3
7	Pre-Emptive Priming of Human Skin Improves Cutaneous Scarring and Is Superior to Immediate and Delayed Topical Anti-Scarring Treatment Post-Wounding: A Double-Blind Randomised Placebo-Controlled Clinical Trial. Pharmaceutics, 2021, 13, 510.	2.0	15
8	Classification of Distinct Endotypes in Human Skin Scarring: S.C.A.R.â€”A Novel Perspective on Dermal Fibrosis. Advances in Wound Care, 2021, , .	2.6	5
9	The surface topography of silicone breast implants mediates the foreign body response in mice, rabbits and humans. Nature Biomedical Engineering, 2021, 5, 1115-1130.	11.6	126
10	Validation strategies for identifying drug targets in dermal fibrotic disorders. Drug Discovery Today, 2021, 26, 2474-2485.	3.2	1
11	Novel Rotational Combination Regimen of Skin Topicals Improves Facial Photoaging: Efficacy Demonstrated in Double-Blinded Clinical Trials and Laboratory Validation. Frontiers in Medicine, 2021, 8, 724344.	1.2	2
12	Editorial: Inflammation in Healing and Regeneration of Cutaneous Wounds. Frontiers in Immunology, 2021, 12, 806687.	2.2	4
13	Laser Treatment of Traumatic Scars and Contractures: 2020 International Consensus Recommendations. Lasers in Surgery and Medicine, 2020, 52, 96-116.	1.1	89
14	16877 Topical rotational treatment induces dermal collagen changes evidenced by immunohistochemistry and confocal Raman spectroscopy. Journal of the American Academy of Dermatology, 2020, 83, AB188.	0.6	0
15	Mast Cells in Skin Scarring: A Review of Animal and Human Research. Frontiers in Immunology, 2020, 11, 552205.	2.2	37
16	A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis. International Journal of Molecular Sciences, 2020, 21, 9673.	1.8	31
17	Fibrosis and diabetes: Chronic hyperglycemia triggers organ-specific fibrotic mechanisms. , 2020, , 121-147.		0
18	A microbiome and metabolomic signature of phases of cutaneous healing identified by profiling sequential acute wounds of human skin: An exploratory study. PLoS ONE, 2020, 15, e0229545.	1.1	24

#	Article	IF	Citations
19	Keloid scarring or disease: Unresolved quasiâ€neoplastic tendencies in the human skin. Wound Repair and Regeneration, 2020, 28, 422-426.	1.5	30
20	Genetics of Keloid Scarring. , 2020, , 61-76.		3
21	Microarchitectural analysis of decellularised unscarred and scarred dermis provides insight into the organisation and ultrastructure of the human skin with implications for future dermal substitute scaffold design. Journal of Tissue Engineering, 2019, 10, 204173141984371.	2.3	14
22	A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in theÂModulation of Cutaneous Scarring inÂHumanÂSkin. Journal of Investigative Dermatology, 2019, 139, 1680-1690.e16.	0.3	36
23	Development of Bioinspired Gelatin and Gelatin/Chitosan Bilayer Hydrofilms for Wound Healing. Pharmaceutics, 2019, 11, 314.	2.0	44
24	Assessment of dermal fibrosis. British Journal of Dermatology, 2019, 181, e98.	1.4	1
25	Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies. Frontiers in Immunology, 2019, 10, 1810.	2.2	97
26	1043 In vitro, in vivo human trial and bioinstrumentational evidence of a novel non-proteogenic amino acid-containing formula shows significant enhancement in skin firming and wrinkle reduction. Journal of Investigative Dermatology, 2019, 139, S180.	0.3	0
27	Functional Testing of a Skin Topical Formulation In Vivo: Objective and Quantitative Evaluation in Human Skin Scarring Using a Double-Blind Volunteer Study with Sequential Punch Biopsies. Advances in Wound Care, 2019, 8, 208-219.	2.6	8
28	Objective assessment of dermal fibrosis in cutaneous scarring, using optical coherence tomography, highâ€frequency ultrasound and immunohistomorphometry of human skin. British Journal of Dermatology, 2019, 181, 722-732.	1.4	26
29	Multiâ€dimensional models for functional testing of keloid scars: In silico, in vitro, organoid, organotypic, ex vivo organ culture, and in vivo models. Wound Repair and Regeneration, 2019, 27, 298-308.	1.5	18
30	çš®è‚çºç»´Œ–è¯„ä¼°. British Journal of Dermatology, 2019, 181, e109.	1.4	0
31	In Vitro and Ex Vivo Models for Functional Testing of Therapeutic Anti-scarring Drug Targets in Keloids. Advances in Wound Care, 2019, 8, 655-670.	2.6	12
32	Electrical stimulation disrupts biofilms in a human wound model and reveals the potential for monitoring treatment response with volatile biomarkers. Wound Repair and Regeneration, 2019, 27, 5-18.	1.5	20
33	Photobiomodulation of a flowable matrix in a human skin ex vivo model demonstrates energyâ€based enhancement of engraftment integration and remodeling. Journal of Biophotonics, 2018, 11, e201800077.	1.1	2
34	Novel Proteomic Assay of Breast Implants Reveals Proteins With Significant Binding Differences: Implications for Surface Coating and Biocompatibility. Aesthetic Surgery Journal, 2018, 38, 962-969.	0.9	12
35	Validation of biofilm formation on human skin wound models and demonstration of clinically translatable bacteria-specific volatile signatures. Scientific Reports, 2018, 8, 9431.	1.6	55
36	Wound healing and cutaneous scarring models of the human skin. , 2018, , 201-221.		3

#	Article	IF	Citations
37	Effects of electrical stimulation on cutaneous wound healing: Evidence from in vitro studies and clinical trials. , 2018, , 373-386.		0
38	Effect of electrical stimulation on bone healing. , 2018, , 387-402.		0
39	Nonâ€animal models of wound healing in cutaneous repair: In silico, in vitro, ex vivo, and in vivo models of wounds and scars in human skin. Wound Repair and Regeneration, 2017, 25, 164-176.	1.5	70
40	Cutaneous wound biofilm and the potential for electrical stimulation in management of the microbiome. Future Microbiology, 2017, 12, 337-357.	1.0	13
41	Therapeutic targets in the management of striae distensae: A systematic review. Journal of the American Academy of Dermatology, 2017, 77, 559-568.e18.	0.6	58
42	Development, fabrication and evaluation of a novel biomimetic human breast tissue derived breast implant surface. Acta Biomaterialia, 2017, 49, 260-271.	4.1	22
43	Volatile organic compound detection as a potential means of diagnosing cutaneous wound infections. Wound Repair and Regeneration, 2017, 25, 574-590.	1.5	26
44	395 Redefining colour and redness in cutaneous healing and scarring: Quantitative evaluation of erythema and pigmentation in human skin corroborated by immunohistochemical analysis. Journal of Investigative Dermatology, 2017, 137, S68.	0.3	0
45	Advances in bioprinted cell-laden hydrogels for skin tissue engineering. Biomanufacturing Reviews, 2017, 2, 1.	4.8	72
46	621 Novel diagnostic approach in detecting skin infection: Identification of bacterial-specific volatile organic compounds in bacterial biofilms on human cutaneous wound models. Journal of Investigative Dermatology, 2017, 137, S107.	0.3	1
47	Functional biocompatibility testing of silicone breast implants and a novel classification system based on surface roughness. Journal of the Mechanical Behavior of Biomedical Materials, 2017, 75, 75-81.	1.5	74
48	Enhanced Neurogenic Biomarker Expression and Reinnervation in HumanÂAcute Skin Wounds Treated by Electrical Stimulation. Journal of Investigative Dermatology, 2017, 137, 737-747.	0.3	22
49	The efficacy of electrical stimulation in lower extremity cutaneous wound healing: A systematic review. Experimental Dermatology, 2017, 26, 171-178.	1.4	54
50	Transforming Growth Factor Beta Gene Signatures are Spatially Enriched in Keloid Tissue Biopsies and Ex vivo-Cultured Keloid Fibroblasts. Acta Dermato-Venereologica, 2017, 97, 10-16.	0.6	14
51	A Role for Neuregulin-1 in Promoting Keloid Fibroblast Migration via ErbB2-mediated Signaling. Acta Dermato-Venereologica, 2017, 97, 675-684.	0.6	18
52	Site-specific gene expression profiling as a novel strategy for unravelling keloid disease pathobiology. PLoS ONE, 2017, 12, e0172955.	1.1	43
53	In Vitro and Ex vivo Analysis of Hyaluronan Supplementation of IntegraÂ® Dermal Template on Human Dermal Fibroblasts and Keratinocytes. Journal of Applied Biomaterials and Functional Materials, 2016, 14, 9-18.	0.7	14
54	The Role of Neuromediators and Innervation in Cutaneous Wound Healing. Acta Dermato-Venereologica, 2016, 96, 587-594.	0.6	76

#	Article	IF	Citations
55	An Innovative Approach to Dissecting Keloid Disease Leading to Identification of the Retinoic Acid Pathway as a Potential Therapeutic Target. Plastic and Reconstructive Surgery - Global Open, 2016, 4, e601.	0.3	1
56	Fabrication and modelling of fractal, biomimetic, micro and nano-topographical surfaces. Bioinspiration and Biomimetics, 2016, 11, 046009.	1.5	0
57	The Aldo-Keto Reductase AKR1B10 Is Up-Regulated in Keloid Epidermis, Implicating Retinoic Acid Pathway Dysregulation in the Pathogenesis of Keloid Disease. Journal of Investigative Dermatology, 2016, 136, 1500-1512.	0.3	20
58	Functional testing of topical skin formulations using an optimised ex vivo skin organ culture model. Archives of Dermatological Research, 2016, 308, 297-308.	1.1	34
59	Identification of a Potential Molecular Diagnostic Biomarker in Keloid Disease: Syndecan-1 (CD138) Is Overexpressed inÂKeloid Scar Tissue. Journal of Investigative Dermatology, 2016, 136, 2319-2323.	0.3	13
60	Whole genome microarray data of chronic wound debridement prior to application of dermal skin substitutes. Wound Repair and Regeneration, 2016, 24, 870-875.	1.5	14
61	Nonâ€invasive objective devices for monitoring the inflammatory, proliferative and remodelling phases of cutaneous wound healing and skin scarring. Experimental Dermatology, 2016, 25, 579-585.	1.4	35
62	Topical management of striae distensae (stretch marks): prevention and therapy of striae rubrae and albae. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 211-222.	1.3	90
63	Epidermal Notch1 recruits RORÎ³+ group 3 innate lymphoid cells to orchestrate normal skin repair. Nature Communications, 2016, 7, 11394.	5.8	76
64	The efficacy of electrical stimulation in experimentally induced cutaneous wounds in animals. Veterinary Dermatology, 2016, 27, 235.	0.4	37
65	IL-33-Dependent Group 2 Innate Lymphoid Cells Promote Cutaneous Wound Healing. Journal of Investigative Dermatology, 2016, 136, 487-496.	0.3	181
66	Noninvasive device readouts validated by immunohistochemical analysis enable objective quantitative assessment of acute wound healing in human skin. Wound Repair and Regeneration, 2015, 23, 901-914.	1.5	14
67	An abnormality in glucocorticoid receptor expression differentiates steroid responders from nonresponders in keloid disease. British Journal of Dermatology, 2015, 173, 690-700.	1.4	10
68	Optimization of an ex vivo wound healing model in the adult human skin: Functional evaluation using photodynamic therapy. Wound Repair and Regeneration, 2015, 23, 685-702.	1.5	43
69	Ex vivo evaluation of the effect of photodynamic therapy on skin scars and striae distensae. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 239-251.	0.7	33
70	Enhanced Contraction of a Normal Breast-Derived Fibroblastâ€“Populated Three-Dimensional Collagen Lattice via Contracted Capsule Fibroblast-Derived Paracrine Factors. Plastic and Reconstructive Surgery, 2015, 135, 1413-1429.	0.7	12
71	Acute Cutaneous Wounds Treated with Human Decellularised Dermis Show Enhanced Angiogenesis during Healing. PLoS ONE, 2015, 10, e0113209.	1.1	25
72	Angiogenesis Is Induced and Wound Size Is Reduced by Electrical Stimulation in an Acute Wound Healing Model in Human Skin. PLoS ONE, 2015, 10, e0124502.	1.1	99

#	Article	IF	Citations
73	Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring. Advances in Wound Care, 2015, 4, 687-703.	2.6	74
74	A comprehensive evidence-based review on the role of topicals and dressings in the management of skin scarring. Archives of Dermatological Research, 2015, 307, 461-477.	1.1	109
75	Skin substituteâ€assisted repair shows reduced dermal fibrosis in acute human wounds validated simultaneously by histology and optical coherence tomography. Wound Repair and Regeneration, 2015, 23, 483-494.	1.5	36
76	Development and functional evaluation of biomimetic silicone surfaces with hierarchical micro/nano-topographical features demonstrates favourable inÂvitro foreign body response of breast-derived fibroblasts. Biomaterials, 2015, 52, 88-102.	5.7	78
77	Electrical Stimulation Enhances Epidermal Proliferation in Human Cutaneous Wounds by Modulating p53â€“SIVA1 Interaction. Journal of Investigative Dermatology, 2015, 135, 1166-1174.	0.3	46
78	Ex vivo evaluation of acellular and cellular collagen-glycosaminoglycan flowable matrices. Biomedical Materials (Bristol), 2015, 10, 041001.	1.7	9
79	Psychometric properties of the Sexual Adjustment Questionnaire (SAQ) in the Iranian population with spinal cord injury. Spinal Cord, 2015, 53, 807-810.	0.9	15
80	Identification of biomarkers involved in differential profiling of hypertrophic and keloid scars versus normal skin. Archives of Dermatological Research, 2015, 307, 115-133.	1.1	31
81	Functional histopathology of keloid disease. Histology and Histopathology, 2015, 30, 1033-57.	0.5	88
82	Superficial Dermal and Fascial Fibromatoses. , 2014, , 1967-1981.		1
83	Electrical Stimulation and Cutaneous Wound Healing: A Review of Clinical Evidence. Healthcare (Switzerland), 2014, 2, 445-467.	1.0	86
84	Skin equivalent tensional force alters keloid fibroblast behavior and phenotype. Wound Repair and Regeneration, 2014, 22, 557-568.	1.5	44
85	Optical coherence tomography: a reliable alternative to invasive histological assessment of acute wound healing in human skin?. British Journal of Dermatology, 2014, 170, 840-850.	1.4	41
86	Silk for dermal tissue engineering. , 2014, , 456-471.		4
87	Chemometrics models for overcoming high between subject variability: applications in clinical metabolic profiling studies. Metabolomics, 2014, 10, 375-385.	1.4	12
88	New Insights on Keloids, Hypertrophic Scars, and Striae. Dermatologic Clinics, 2014, 32, 193-209.	1.0	83
89	Striae distensae: a comprehensive review and evidence-based evaluation of prophylaxis and treatment. British Journal of Dermatology, 2014, 170, 527-547.	1.4	150
90	Regenerative healing, scarâ€free healing and scar formation across the species: current concepts and future perspectives. Experimental Dermatology, 2014, 23, 615-619.	1.4	58

#	Article	IF	Citations
91	Physico-chemical characteristics of coated silicone textured versus smooth breast implants differentially influence breast-derived fibroblast morphology and behaviour. Journal of the Mechanical Behavior of Biomedical Materials, 2014, 40, 140-155.	1.5	9
92	Contracted capsule fibroblast conditioned media induces increased contraction of a normal breast tissue derived fibroblast-populated 3D collagen lattice via paracrine signalling. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2014, 67, 1461.	0.5	0
93	Rheology and Electrospinning of Regenerated Bombyx mori Silk Fibroin Aqueous Solutions. Biomacromolecules, 2014, 15, 1288-1298.	2.6	35
94	Electrospun silk fibroin fiber diameter influences in vitro dermal fibroblast behavior and promotes healing of ex vivo wound models. Journal of Tissue Engineering, 2014, 5, 204173141455166.	2.3	87
95	First Identification of Resident and Circulating Fibrocytes in Dupuytrenâ€™s Disease Shown to Be Inhibited by Serum Amyloid P and Xiapex. PLoS ONE, 2014, 9, e99967.	1.1	8
96	Use of Novel Biomaterial Design and Stem Cell Therapy in Cutaneous Wound Healing. , 2013, , 27-42.		0
97	A double-blind controlled clinical trial assessing the effect of topical gels on striae distensae (stretch marks): a non-invasive imaging, morphological and immunohistochemical study. Archives of Dermatological Research, 2013, 305, 603-617.	1.1	28
98	Identification of steroid sensitive responders versus non-responders in the treatment of keloid disease. Archives of Dermatological Research, 2013, 305, 423-432.	1.1	22
99	Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools. Archives of Dermatological Research, 2013, 305, 205-214.	1.1	57
100	Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. Journal of Dermatological Science, 2013, 72, 206-217.	1.0	376
101	Ex vivo evaluation of antifibrotic compounds in skin scarring: EGCG and silencing of PAI-1 independently inhibit growth and induce keloid shrinkage. Laboratory Investigation, 2013, 93, 946-960.	1.7	49
102	The Impact of Dupuytren Disease on Patient Activity and Quality of Life. Journal of Hand Surgery, 2013, 38, 1209-1214.	0.7	65
103	Strategic management of keloid disease in ethnic skin: a structured approach supported by the emerging literature. British Journal of Dermatology, 2013, 169, 71-81.	1.4	70
104	Interactions of the Extracellular Matrix and Progenitor Cells in Cutaneous Wound Healing. Advances in Wound Care, 2013, 2, 261-272.	2.6	44
105	Potent Dual Inhibitors of TORC1 and TORC2 Complexes (KU-0063794 and KU-0068650) Demonstrate In Vitro and Ex Vivo Anti-Keloid Scar Activity. Journal of Investigative Dermatology, 2013, 133, 1340-1350.	0.3	37
106	Characterisation of breast implant surfaces and correlation with fibroblast adhesion. Journal of the Mechanical Behavior of Biomedical Materials, 2013, 21, 133-148.	1.5	55
107	Superior effect of combination vs. single steroid therapy in keloid disease: A comparative in vitro analysis of glucocorticoids. Wound Repair and Regeneration, 2013, 21, 88-102.	1.5	20
108	The role of skin substitutes in the management of chronic cutaneous wounds. Wound Repair and Regeneration, 2013, 21, 194-210.	1.5	107

#	Article	IF	Citations
109	Designing implant surface topography for improved biocompatibility. Expert Review of Medical Devices, 2013, 10, 257-267.	1.4	113
110	Isolated and Spontaneous Correction of Proximal Interphalangeal Joint Contractures in Dupuytrenâ€™s Disease: An Exploratory Analysis of the Efficacy and Safety of Collagenase Clostridium histolyticum. Clinical Drug Investigation, 2013, 33, 905-912.	1.1	12
111	Altered expression of hyaluronan synthase and hyaluronidase mRNA may affect hyaluronic acid distribution in keloid disease compared with normal skin. Experimental Dermatology, 2013, 22, 377-379.	1.4	25
112	Singleâ€stage application of a novel decellularized dermis for treatmentâ€resistant lower limb ulcers: Positive outcomes assessed by <scp>SIA</scp>scopy, laser perfusion, and 3<scp>D</scp> imaging, with sequential timed histological analysis. Wound Repair and Regeneration, 2013, 21, 813-822.	1.5	23
113	Identification of molecular phenotypic descriptors of breast capsular contracture formation using informatics analysis of the whole genome transcriptome. Wound Repair and Regeneration, 2013, 21, 762-769.	1.5	22
114	Up-Regulation of Tension-Related Proteins in Keloids. Plastic and Reconstructive Surgery, 2013, 131, 158e-173e.	0.7	30
115	Enhancement of Differentiation and Mineralisation of Osteoblast-like Cells by Degenerate Electrical Waveform in an In Vitro Electrical Stimulation Model Compared to Capacitive Coupling. PLoS ONE, 2013, 8, e72978.	1.1	29
116	Site-Specific Keloid Fibroblasts Alter the Behaviour of Normal Skin and Normal Scar Fibroblasts through Paracrine Signalling. PLoS ONE, 2013, 8, e75600.	1.1	73
117	Significant reduction of symptoms of scarring with electrical stimulation: evaluated with subjective and objective assessment tools in a prospective noncontrolled case series. Wounds, 2013, 25, 212-24.	0.2	10
118	Understanding Dupuytren's Disease Using Systems Biology: A Move Away from Reductionism. Frontiers in Physiology, 2012, 3, 316.	1.3	2
119	Unpicking Dupruyten Disease etiologyâ€”is Wnt the way?. Nature Reviews Rheumatology, 2012, 8, 5-6.	3.5	4
120	Dupuytrenâ€™s disease: overview of a common connective tissue disease with a focus on emerging treatment options. International Journal of Clinical Rheumatology, 2012, 7, 309-323.	0.3	10
121	DNA Copy Number Variations at Chromosome 7p14.1 and Chromosome 14q11.2 Are Associated with DupuytrenÊ¼s Disease. Plastic and Reconstructive Surgery, 2012, 129, 921-932.	0.7	20
122	Notch signaling pathway in keloid disease: Enhanced fibroblast activity in a <scp>J</scp>aggedâ€1 peptideâ€dependent manner in lesional vs. extralesional fibroblasts. Wound Repair and Regeneration, 2012, 20, 688-706.	1.5	50
123	Identification of biomarkers in sequential biopsies of patients with chronic wounds receiving simultaneous acute wounds: A genetic, histological, and noninvasive imaging study. Wound Repair and Regeneration, 2012, 20, 757-769.	1.5	14
124	Electrical stimulation increases blood flow and haemoglobin levels in acute cutaneous wounds without affecting wound closure time: evidenced by nonâ€invasive assessment of temporal biopsy wounds in human volunteers. Experimental Dermatology, 2012, 21, 758-764.	1.4	32
125	Identification of fibrocytes from mesenchymal stem cells in keloid tissue: a potential source of abnormal fibroblasts in keloid scarring. Archives of Dermatological Research, 2012, 304, 665-671.	1.1	37
126	Differential cytotoxic response in keloid fibroblasts exposed to photodynamic therapy is dependent on photosensitiser precursor, fluence and location of fibroblasts within the lesion. Archives of Dermatological Research, 2012, 304, 549-562.	1.1	20

#	Article	IF	Citations
127	Identification of Mesenchymal Stem Cells in Perinodular Fat and Skin in Dupuytren's Disease: A Potential Source of Myofibroblasts with Implications for Pathogenesis and Therapy. Stem Cells and Development, 2012, 21, 609-622.	1.1	28
128	Dupuytren's disease metabolite analyses reveals alterations following initial short-term fibroblast culturing. Molecular BioSystems, 2012, 8, 2274.	2.9	17
129	Site-specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates. British Journal of Dermatology, 2012, 167, 1053-1066.	1.4	112
130	Keloid Disease Can Be Inhibited by Antagonizing Excessive mTOR Signaling With a Novel Dual TORC1/2 Inhibitor. American Journal of Pathology, 2012, 181, 1642-1658.	1.9	43
131	Whole genome and global expression profiling of Dupuytren's disease: systematic review of current findings and future perspectives. Annals of the Rheumatic Diseases, 2012, 71, 1440-1447.	0.5	21
132	Comparative genomic hybridisation analysis of keloid tissue in Caucasians suggests possible involvement of HLA-DRB5 in disease pathogenesis. Archives of Dermatological Research, 2012, 304, 241-249.	1.1	30
133	Extracellular matrix molecules implicated in hypertrophic and keloid scarring. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 141-152.	1.3	162
134	Longâ€term organ culture of keloid disease tissue. Experimental Dermatology, 2012, 21, 376-381.	1.4	51
135	In Vitro Study of Novel Collagenase (XIAFLEXÂ®) on Dupuytren's Disease Fibroblasts Displays Unique Drug Related Properties. PLoS ONE, 2012, 7, e31430.	1.1	50
136	High Prevalence of Dupuytrenâ€™s Disease and Its Treatment in the British National Health Service: An Ongoing Demand. , 2012, , 27-34.		0
137	Dupuytrenâ€™s Disease Shows Populations of Hematopoietic and Mesenchymal Stem-Like Cells Involving Perinodular Fat and Skin in Addition to Diseased Fascia: Implications for Pathogenesis and Therapy. , 2012, , 167-174.		1
138	Use of Genetic and Genomic Analyses Tools to Study Dupuytrenâ€™s Disease. , 2012, , 93-100.		0
139	Extensive self-harm scarring: successful treatment with simultaneous use of a single layer skin substitute and split-thickness skin graft. Eplasty, 2012, 12, e23.	0.4	10
140	Dupuytren's: a systems biology disease. Arthritis Research and Therapy, 2011, 13, 238.	1.6	36
141	Breast Implant Surface Development: Perspectives on Development and Manufacture. Aesthetic Surgery Journal, 2011, 31, 56-67.	0.9	64
142	Addition of novel degenerate electrical waveform stimulation with photodynamic therapy significantly enhances its cytotoxic effect in keloid fibroblasts: First report of a potential combination therapy. Journal of Dermatological Science, 2011, 64, 174-184.	1.0	22
143	Degenerate Wave and Capacitive Coupling Increase Human MSC Invasion and Proliferation While Reducing Cytotoxicity in an In Vitro Wound Healing Model. PLoS ONE, 2011, 6, e23404.	1.1	52
144	A Clinical Characterization of Familial Keloid Disease in Unique African Tribes Reveals Distinct Keloid Phenotypes. Plastic and Reconstructive Surgery, 2011, 127, 689-702.	0.7	17

#	Article	IF	Citations
145	Reply: Patient Assessments of Scarring: Patient-Reported Impact of Scars Measure or Patient Scar Assessment Questionnaire?. Plastic and Reconstructive Surgery, 2011, 127, 1745-1746.	0.7	1
146	Reply: Is Adherent Scar Always Nonpliable?. Plastic and Reconstructive Surgery, 2011, 127, 2519-2520.	0.7	2
147	Hyaluronan, TSG-6, and Inter-Î±-Inhibitor in Periprosthetic Breast Capsules: Reduced Levels of Free Hyaluronan and TSG-6 Expression in Contracted Capsules. Aesthetic Surgery Journal, 2011, 31, 47-55.	0.9	16
148	Assessment of the influence of HLA class I and class II loci on the prevalence of keloid disease in Jamaican Afroâ€Caribbeans. Tissue Antigens, 2011, 78, 390-396.	1.0	2
149	Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. British Journal of Dermatology, 2011, 164, 83-96.	1.4	148
150	Acceleration of cutaneous healing by electrical stimulation: Degenerate electrical waveform downâ€regulates inflammation, upâ€regulates angiogenesis and advances remodeling in temporal punch biopsies in a human volunteer study. Wound Repair and Regeneration, 2011, 19, 693-708.	1.5	81
151	Characterization of hyaluronan and TSGâ€6 in skin scarring: differential distribution in keloid scars, normal scars and unscarred skin. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 317-327.	1.3	64
152	A novel in vitro assay for electrophysiological research on human skin fibroblasts: Degenerate electrical waves downregulate collagen I expression in keloid fibroblasts. Experimental Dermatology, 2011, 20, 64-68.	1.4	25
153	Dermal substitute-assisted healing: enhancing stem cell therapy with novel biomaterial design. Archives of Dermatological Research, 2011, 303, 301-315.	1.1	49
154	Cellular Senescence as a Possible Mechanism for Halting Progression of Keloid Lesions. Genes and Cancer, 2011, 2, 1061-1066.	0.6	24
155	Exploring the application of mesenchymal stem cells in bone repair and regeneration. Journal of Bone and Joint Surgery: British Volume, 2011, 93-B, 427-434.	3.4	99
156	Upregulation of Toll-Like Receptors (TLRs) 6, 7, and 8 in Keloid Scars. Journal of Investigative Dermatology, 2011, 131, 2128-2130.	0.3	16
157	The Influence of Surgical Excision Margins on Keloid Prognosis. Annals of Plastic Surgery, 2010, 64, 55-58.	0.5	40
158	The Patient-Reported Impact of Scars Measure: Development and Validation. Plastic and Reconstructive Surgery, 2010, 125, 1439-1449.	0.7	68
159	Current Tools for Noninvasive Objective Assessment of Skin Scars. Plastic and Reconstructive Surgery, 2010, 126, 912-923.	0.7	116
160	Genetics of keloid scarring. Archives of Dermatological Research, 2010, 302, 319-339.	1.1	210
161	Phenotypic profiling of keloid scars using FT-IR microspectroscopy reveals a unique spectral signature. Archives of Dermatological Research, 2010, 302, 705-715.	1.1	18
162	Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option. Archives of Dermatological Research, 2010, 302, 725-731.	1.1	59

#	Article	IF	Citations
163	Role of the HLA System in the Pathogenesis of Dupuytren's Disease. Hand, 2010, 5, 241-250.	0.7	15
164	Characterization of stem cells in Dupuytren's disease. British Journal of Surgery, 2010, 98, 308-315.	0.1	22
165	Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair and Regeneration, 2010, 18, 139-153.	1.5	206
166	Novel noninvasive identification of biomarkers by analytical profiling of chronic wounds using volatile organic compounds. Wound Repair and Regeneration, 2010, 18, 391-400.	1.5	78
167	Positive response of a recurrent keloid scar to topical methyl aminolevulinate-photodynamic therapy. Photodermatology Photoimmunology and Photomedicine, 2010, 26, 330-332.	0.7	39
168	Differential distribution of haematopoietic and nonhaematopoietic progenitor cells in intralesional and extralesional keloid: do keloid scars provide a niche for nonhaematopoietic mesenchymal stem cells?. British Journal of Dermatology, 2010, 162, 1377-1383.	1.4	30
169	Association of HLA-DRB1* and keloid disease in an Afro-Caribbean population. Clinical and Experimental Dermatology, 2010, 35, 305-310.	0.6	18
170	The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease. Therapeutics and Clinical Risk Management, 2010, Volume 6, 557-572.	0.9	44
171	Tumour Necrosis Factor-Î± Expression Is Associated with Increased Severity of Periprosthetic Breast Capsular Contracture. European Surgical Research, 2010, 45, 327-332.	0.6	36
172	Scientific understanding and clinical management of Dupuytren disease. Nature Reviews Rheumatology, 2010, 6, 715-726.	3.5	134
173	Influence of the Human Leukocyte Antigen Complex on the Development of Cutaneous Fibrosis: An Immunogenetic Perspective. Acta Dermato-Venereologica, 2010, 90, 563-574.	0.6	10
174	Treatment of symptomatic abnormal skin scars with electrical stimulation. Journal of Wound Care, 2010, 19, 447-453.	0.5	23
175	A nonsurgical therapy for Dupuytren disease. Nature Reviews Rheumatology, 2010, 6, 7-8.	3.5	9
176	Skin scar preconceptions must be challenged: Importance of self-perception in skin scarring. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2010, 63, 1022-1029.	0.5	99
177	Genome-Wide High-Resolution Screening in Dupuytren's Disease Reveals Common Regions of DNA Copy Number Alterations. Journal of Hand Surgery, 2010, 35, 1172-1183.e7.	0.7	14
178	Assessing the severity of inhalation injuries in adults. Burns, 2010, 36, 212-216.	1.1	73
179	Identification of novel keloid biomarkers through profiling of tissue biopsies versus cell cultures in keloid margin specimens compared to adjacent normal skin. Eplasty, 2010, 10, e24.	0.4	28
180	Epidemiological Evaluation of Dupuytren's Disease Incidence and Prevalence Rates in Relation to Etiology. Hand, 2009, 4, 256-269.	0.7	161

#	Article	IF	Citations
181	Differential Gene Expression Analysis of Subcutaneous Fat, Fascia, and Skin Overlying a Dupuytren's Disease Nodule in Comparison to Control Tissue. Hand, 2009, 4, 294-301.	0.7	23
182	Genetic susceptibility to raised dermal scarring. British Journal of Dermatology, 2009, 161, 8-18.	1.4	155
183	Exploring the role of stem cells in cutaneous wound healing. Experimental Dermatology, 2009, 18, 921-933.	1.4	242
184	Basic fibroblast growth factor: A potential new therapeutic tool for the treatment of hypertrophic and keloid scars. Annals of Anatomy, 2009, 191, 33-44.	1.0	56
185	Identification of Biomarkers in Dupuytren's Disease by Comparative Analysis of Fibroblasts Versus Tissue Biopsies in Disease-Specific Phenotypes. Journal of Hand Surgery, 2009, 34, 124-136.	0.7	43
186	Keloid scar harbouring malignant blue naevus emphasises the need for excision biopsy and routine histology. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2009, 62, 93-95.	0.5	8
187	Adult stem cells in tissue engineering. Expert Review of Medical Devices, 2009, 6, 621-640.	1.4	37
188	Current implant surface technology: an examination of their nanostructure and their influence on fibroblast alignment and biocompatibility. Eplasty, 2009, 9, e22.	0.4	65
189	Revised Tubiana's Staging System for Assessment of Disease Severity in Dupuytren's Diseaseâ€"Preliminary Clinical Findings. Hand, 2008, 3, 80-86.	0.7	24
190	Genetic susceptibility to Keloid scarring: SMAD gene SNP frequencies in Afroâ€Caribbeans. Experimental Dermatology, 2008, 17, 610-613.	1.4	47
191	Identification of unique gene expression patterns within different lesional sites of keloids. Wound Repair and Regeneration, 2008, 16, 254-265.	1.5	90
192	Positive association of HLAâ€ÐRB1*15 with keloid disease in Caucasians. International Journal of Immunogenetics, 2008, 35, 303-307.	0.8	51
193	Levels of evidence for the treatment of keloid disease. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2008, 61, 4-17.	0.5	101
194	The hidden cost of skin scars: quality of life after skin scarring. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2008, 61, 1049-1058.	0.5	389
195	Molecular Phenotypic Descriptors of Dupuytrenâ€™s Disease Defined Using Informatics Analysis of the Transcriptome. Journal of Hand Surgery, 2008, 33, 359-372.	0.7	54
196	Positive association of HLAâ€ÐRB1*15 with Dupuytrenâ€™s disease in Caucasians. Tissue Antigens, 2008, 72, 166-170.	1.0	27
197	RAC activity in keloid disease: comparative analysis of fibroblasts from margin of keloid to its surrounding normal skin. Eplasty, 2008, 8, e19.	0.4	15
198	Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor. Annals of the Rheumatic Diseases, 2007, 66, 1116-1120.	0.5	74

#	Article	IF	Citations
199	Assessment of clinical severity in Dupuytren's disease. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT /Over	0.2	36
200	Optimal Plaster Conformation Derived Using a Custom-Made Jig to Obtain Maximum Strength of Protective Plaster of Paris for Hand Surgery. Journal of Trauma, 2007, 63, 1074-1078.	2.3	5
201	Genetic Susceptibility to Total Hip Arthroplasty Failureâ€"Positive Association With Mannose-Binding Lectin. Journal of Arthroplasty, 2007, 22, 265-270.	1.5	33
202	Transforming growth factor beta (TGFÎ²) and keloid disease. International Journal of Surgery, 2007, 5, 278-285.	1.1	109
203	Current use of steroids in management of abnormal raised skin scars. Journal of the Royal College of Surgeons of Edinburgh, 2007, 5, 175-180.	0.8	88
204	Use of a non-contact 3D digitiser to measure the volume of keloid scars: a useful tool for scar assessment. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2007, 60, 87-94.	0.5	40
205	Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-beta receptor II. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2007, 60, 73-74.	0.5	2
206	Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2006, 59, 221-229.	0.5	54
207	Modernising medical careers in the UK and plastic surgery as a possible career choice: undergraduate opinions. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2006, 59, 1472-1474.	0.5	12
208	The Heritability of Dupuytrenâ€™s Disease: Familial Aggregation and Its Clinical Significance. Journal of Hand Surgery, 2006, 31, 204-210.	0.7	96
209	Dupuytrenâ€™s Diathesis Revisited: Evaluation of Prognostic Indicators for Risk of Disease Recurrence. Journal of Hand Surgery, 2006, 31, 1626-1634.	0.7	160
210	Management of Dupuytren's Disease â€“ Clear Advice for an Elusive Condition. Annals of the Royal College of Surgeons of England, 2006, 88, 3-8.	0.3	105
211	Manual Graft Meshing: Taking It Further. Plastic and Reconstructive Surgery, 2006, 117, 340-341.	0.7	1
212	Genetic susceptibility to hip arthroplasty failureâ€"association with the RANK/OPG pathway. International Orthopaedics, 2006, 30, 177-181.	0.9	33
213	Common Peroneal Nerve Injury During Varicose Vein Operation. European Journal of Vascular and Endovascular Surgery, 2006, 31, 443-445.	0.8	10
214	Dupuytrenâ€™s disease. Surgery, 2006, 24, 373-375.	0.1	0
215	Spectrum of abnormal skin scars and their clinical management. British Journal of Hospital Medicine (London, England: 2005), 2006, 67, 527-532.	0.2	14
216	Keloid disease: clinical relevance of single versus multiple site scars. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2005, 58, 28-37.	1.1	128

#	Article	IF	Citations
217	Heterotopic nasopharyngeal brain tissue associated with cleft palate. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2005, 58, 862-864.	1.1	9
218	Genetic susceptibility to keloid disease: mutation screening of the TGFÎ²3 gene. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2005, 58, 914-921.	1.1	41
219	Mitochondrial mutation detection using enhanced multiplex denaturing high-performance liquid chromatography. International Journal of Immunogenetics, 2005, 32, 199-205.	0.8	8
220	Studies of Transforming Growth Factors Beta 1-3 and their Receptors I and II in Fibroblast of Keloids and Hypertrophic Scars. Acta Dermato-Venereologica, 2005, -1, 1-1.	0.6	43
221	Clinical Management of Skin Scarring. Skinmed, 2005, 4, 165-173.	0.0	52
222	Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plastic and Reconstructive Surgery, 2005, 115, 134-41.	0.7	39
223	Genetic susceptibility to keloid disease: Transforming growth factor beta receptor gene polymorphisms are not associated with keloid disease. Experimental Dermatology, 2004, 13, 120-124.	1.4	42
224	Description of site-specific morphology of keloid phenotypes in an Afrocaribbean population. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2004, 57, 122-133.	1.1	92
225	Dissection of Complex Genetic Disease. Clinical Orthopaedics and Related Research, 2004, 419, 297-305.	0.7	5
226	Rapid denaturing high-performance liquid chromatography (DHPLC) for mutation scanning of the transforming growth factor Î²3 gene using a novel proof-reading polymerase. International Journal of Immunogenetics, 2003, 30, 335-340.	1.2	2
227	Continuous intravenous versus bolus parenteral midazolam: a safe technique for conscious sedation in plastic surgery. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2003, 56, 272-275.	1.1	12
228	Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFÎ²R) gene polymorphisms and Dupuytren's disease. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2003, 56, 328-333.	1.1	38
229	Implications for Burns Unit design following outbreak of multi-resistant Acinetobacter infection in ICU and Burns Unit. Burns, 2003, 29, 303-306.	1.1	42
230	Skin scarring. BMJ: British Medical Journal, 2003, 326, 88-92.	2.4	534
231	THE TENDON PIN: A MODIFIED SAFETY PIN FOR TENDON SURGERY. Plastic and Reconstructive Surgery, 2003, 111, 1356-1357.	0.7	1
232	'Aggressive keloid': a severe variant of familial keloid scarring. Journal of the Royal Society of Medicine, 2003, 96, 554-555.	1.1	17
233	Genetic Susceptibility to Keloid Disease and Hypertrophic Scarring: Transforming Growth Factor Î²1 Common Polymorphisms and Plasma Levels. Plastic and Reconstructive Surgery, 2003, 111, 535-543.	0.7	86
234	Genetic Susceptibility to Dupuytren Disease: Association of Zf9 Transcription Factor Gene. Plastic and Reconstructive Surgery, 2003, 111, 2133-2139.	0.7	56

#	Article	IF	Citations
235	â€˜Aggressive Keloidâ€™: A Severe Variant of Familial Keloid Scarring. Journal of the Royal Society of Medicine, 2003, 96, 554-555.	1.1	5
236	Science, medicine, and the future: Bioinformatics. BMJ: British Medical Journal, 2002, 324, 1018-1022.	2.4	138
237	The pulley system of the thumb: Anatomic and biomechanical study. Journal of Hand Surgery, 2002, 27, 628-635.	0.7	70
238	Genetic Susceptibility in Dupuytrenâ€™s Disease: Lack of Association of a Novel Transforming Growth Factor Î²2Polymorphism in Dupuytrenâ€™s Disease. Journal of Hand Surgery, 2002, 27, 47-49.	0.9	24
239	Genetic susceptibility in Dupuytrenâ€™s disease. Journal of Bone and Joint Surgery: British Volume, 2002, 84-B, 211-215.	3.4	6
240	Necrotising fasciitis in an infant with congenital insensitivity to pain syndrome. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2002, 55, 160-163.	1.1	10
241	Genetic susceptibility to keloid disease and transforming growth factor Î²2 polymorphisms. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2002, 55, 283-286.	1.1	41
242	Novel single nucleotide polymorphisms in the 3â€²-UTR of the TGFÎ²RI and TGFÎ²RIII genes. International Journal of Immunogenetics, 2002, 29, 445-446.	1.2	4
243	Genetic susceptibility in Dupuytren's disease. TGF-beta1 polymorphisms and Dupuytren's disease. Journal of Bone and Joint Surgery: British Volume, 2002, 84, 211-5.	3.4	33
244	Two novel polymorphisms in the human transforming growth factor beta 2 gene. Genes and Immunity, 2001, 2, 295-296.	2.2	8